Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone

Denosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT. Denosumab has also been used pre-operatively to downstage tumours with large soft tissue extension...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Sarcoma Res
Главные авторы: Gaston, Czar Louie, Grimer, Robert J., Parry, Michael, Stacchiotti, Silvia, Dei Tos, Angelo Paolo, Gelderblom, Hans, Ferrari, Stefano, Baldi, Giacomo G., Jones, Robin L., Chawla, Sant, Casali, Paolo, LeCesne, Axel, Blay, Jean-Yves, Dijkstra, Sander P. D., Thomas, David M., Rutkowski, Piotr
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2016
Предметы:
Review
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5022265/
https://ncbi.nlm.nih.gov/pubmed/27651889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13569-016-0056-0
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы